MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
MYRIAD GENETICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$4.21+0.23 (+5.78%)
Close on Oct 19, 2026
- Market cap
- $399.11M
- P/E (TTM)
- –
- Dividend yield
- –
MYRIAD GENETICS INC revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacogenomics | – | – | – | $148.10M | $157.10M | $162.30M | $170.20M | $165.20M | $153.20M | $145.40M | $138.50M | $135.00M | – | – |
| Prenatal | – | – | – | – | – | – | – | $172.20M | $168.20M | $159.40M | $151.30M | $140.40M | – | – |
| Tumor Profiling | – | – | $121.70M | $120.90M | $123.00M | $124.20M | $125.80M | $127.20M | $125.80M | $129.20M | $135.60M | $135.20M | – | – |
| Hereditary Cancer | – | – | – | – | – | – | – | $359.00M | $355.00M | $340.20M | $327.80M | $323.80M | – | – |
| Autoimmune | – | – | – | – | – | – | – | – | – | – | $0 | – | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $752.70M | $773.40M | $768.00M | $767.00M | $771.30M | $767.90M | $769.50M | $750.30M | $726.50M | $694.10M | $671.70M | $652.40M | 93.3% | -2.4% |
| RoW | $53.90M | $55.60M | $56.50M | $58.30M | $61.60M | $63.40M | $68.10M | $73.30M | $75.70M | $80.10M | $81.50M | $82.00M | 6.7% | -12.5% |
From the segment and revenue-disaggregation notes of Myriad Genetics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.